menu
    • menu
    [{"orgOrder":0,"company":"Pharmavite","sponsor":"Biofortis M\u00e9rieux Nutriscience","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"S-Equol","moa":"Estrogen receptor beta; Sex hormone-binding globulin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmavite \/ Biofortis M\u00e9rieux Nutriscience","highestDevelopmentStatusID":"1","companyTruncated":"Pharmavite \/ Biofortis M\u00e9rieux Nutriscience"},{"orgOrder":0,"company":"Pharmavite","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ KGK Science","highestDevelopmentStatusID":"6","companyTruncated":"Pharmavite \/ KGK Science"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Pharmavite","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"Prostaglandin G\/H synthase 2; Prostaglandin G\/H synthase 1; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta; Free fatty acid receptor 1; Sodium\/calcium exchanger 1; Fatty acid-binding protein, brain; Acyl-CoA (8-3)-desaturase; Long-chain-fatty-acid--CoA ligase 4; Transient receptor potential cation channel subfamily V member 1; Peroxisome proliferator-activated receptor alpha; Polyunsaturated fatty acid 5-lipoxygenase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Pharmavite","highestDevelopmentStatusID":"1","companyTruncated":"Pharmavite \/ Pharmavite"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Bonafide Health","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Bonafide Pollen","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmavite \/ Pharmavite","highestDevelopmentStatusID":"15","companyTruncated":"Pharmavite \/ Pharmavite"},{"orgOrder":0,"company":"Bonafide Health","sponsor":"Lindus Health","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Bonafide-HF3.0","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Bonafide Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bonafide Health \/ Lindus Health","highestDevelopmentStatusID":"1","companyTruncated":"Bonafide Health \/ Lindus Health"},{"orgOrder":0,"company":"Bonafide Health","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"JDS-HF","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Bonafide Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bonafide Health \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Bonafide Health \/ Nutrasource"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Triglyceride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"Pharmavite \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Pharmavite","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Pharmavite","highestDevelopmentStatusID":"1","companyTruncated":"Pharmavite \/ Pharmavite"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase I","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmavite \/ Undisclosed"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Atlantia Food Clinical Trials Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Atlantia Food Clinical Trials Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Pharmavite \/ Atlantia Food Clinical Trials Ltd."},{"orgOrder":0,"company":"Pharmavite","sponsor":"Juan Celedon","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Juan Celedon","highestDevelopmentStatusID":"8","companyTruncated":"Pharmavite \/ Juan Celedon"}]

    Find Clinical Drug Pipeline Developments & Deals by Pharmavite

    Menu

    Pharmavite

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Sleep

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of Nutritional Supplementation on Sleep Quality

                            Details : This drug candidate is currently being evaluated in phase I clinical studies for the treatment of Sleep.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 20, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Atlantia Food Clinical Trials Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of a Nutritional Supplement on Gut Microbiota in Adults

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Dysbiosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 24, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Atlantia Food Clinical Trials Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bonafide Health

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Bonafide Health

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bonafide-HF3.0

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Undisclosed

                            Sponsor : Lindus Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hot Flash and Night Sweat Virtual Study

                            Details : Bonafide-HF3.0 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 04, 2024

                            Lead Product(s) : Bonafide-HF3.0

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Undisclosed

                            Sponsor : Lindus Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bonafide Pollen

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : Bonafide Health

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Pharmavite, a U.S. Subsidiary of Otsuka Pharmaceutical, Acquires Bonafide Health, a Provider of Women's Health...

                            Details : Through the acquisition, Pharmavite will expand its portfolio of women's health by including Relizen (bonafide pollen), a plant-based & hormone-free supplement, which is safe to use for menopause relief.

                            Product Name : Relizen

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 30, 2023

                            Lead Product(s) : Bonafide Pollen

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : Bonafide Health

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triglyceride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Sponsor : Atlantia Food Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of a Nutritional Supplement on Mental Wellness in Adults

                            Details : Triglyceride is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Depression.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            September 28, 2023

                            Lead Product(s) : Triglyceride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Sponsor : Atlantia Food Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bonafide Health

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Bonafide Health

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JDS-HF

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Undisclosed

                            Sponsor : Nutrasource

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women

                            Details : JDS-HF is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hot Flashes.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            April 14, 2023

                            Lead Product(s) : JDS-HF

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Undisclosed

                            Sponsor : Nutrasource

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Midwest Center for Metabolic and Cardiovascular Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability of Select Nutrients From Two Formulations of a Multivitamin/Mineral Supplement

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 12, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Midwest Center for Metabolic and Cardiovascular Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S-Equol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Undisclosed

                            Sponsor : Biofortis Mérieux Nutriscience

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Nutritional Supplement on Vasomotor Symptoms in Women

                            Details : S-equol is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            August 18, 2020

                            Lead Product(s) : S-Equol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Undisclosed

                            Sponsor : Biofortis Mérieux Nutriscience

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : KGK Science

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Pharmacokinetics of Prolonged-release Melatonin Compared to Standard, Immediate-rel...

                            Details : Melatonin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 26, 2019

                            Lead Product(s) : Melatonin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : KGK Science

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pharmavite

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Midwest Center for Metabolic and Cardiovascular Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability of EPA + DHA in a SMEDS Formulation

                            Details : Eicosapentaenoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 22, 2018

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Midwest Center for Metabolic and Cardiovascular Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth